IL-10 is an important regulatory cytokine. The recent characterization of the 5Ј-flanking region of IL-10 led to the identification of the promoter region. The infection of B cells with EBV induces IL-10 production which may contribute to EBV-induced transformation. In the present report, IL-10 promoter elements involved in the constitutive expression of IL-10 in EBV-positive lymphoma cells are described. The AT-rich region between −54/−66 from the transcriptional start site was found to be important for IL-10-promoter activity in BL36. A point mutation at position −60 (T/A) was associated with over 90% reduction of luciferase activity in the cell lines BL36 and BL74. The conversion of A/T at position −57 led to enhanced promoter activity. In addition the AT-rich region could serve as an enhancer for the ␤-globin basic promoter. In BJAB cells (EBV-negative), sequences between −205/−139 rather than the AT-rich region were involved in IL-10 promoter regulation. This underlines the importance of the AT-rich region for EBV-associated IL-10 promoter regulation. Our results further the understanding of how the IL-10 gene could be regulated in B cell lymphomas.
Introduction
The recent characterization of interleukin-10 (IL-10) as an important multifunctional cytokine has led to the recognition that it is a key component of many aspects of the immune response.
1,2 IL-10 exerts a wide spectrum of in vitro and in vivo biological activities implicated in the regulation of the inflammatory and immune responses. The influence of IL-10 in the basic biology of the human immune system is reflected in its involvement with a range of malignant diseases. The ability of IL-10 to block activation of cytokine synthesis and several accessory cell functions renders this cytokine a potent suppressor of the effector functions of macrophages, T cells, NK cells. 3 Among the different cell types affected by interleukin-10, monocyte/macrophages and lymphocytes appear to be particularly modified with regard to their function, morphology, and phenotype. IL-10 is a potent modulator of polymorphonuclear neutrophils. 4 In addition IL-10 may contribute to the regulation of proliferation and differentiation of B cells and the growth of human B cell lymphomas, where its expression can be profoundly dysreg- ulated. [5] [6] [7] [8] [9] Recent reports indicate that this cytokine may contribute to Epstein-Barr virus (EBV)-associated transformation. It has been shown that IL-10 is an autocrine growth factor for AIDS-associated lymphoma cells in vitro and that IL-10 is a pathogenic factor for lymphoma development in huSCID-mice. [7] [8] [9] Increased levels of IL-10 were detected in sera of patients with non-Hodgkin lymphomas (NHL). [10] [11] [12] The expression of IL-10 appears to be tightly regulated since the levels of constitutive expression in normal cells are extremely low. 2 It has been shown that in contrast to normal hematopoietic cells, in EBV-immortalized B cells, EBV-positive Burkitt's lymphoma (BL) cells and in CD40 stimulated B cells, IL-10 is expressed. 6, [13] [14] [15] [16] However, the mechanism of the IL-10 induction in B cells is still unclear. 15, 17, 18 IL-10 induction by stimulation of human blood cultures with bacterial lipopolysaccharide (LPS) was found to be TNF and cAMP-dependent and shows large interindividual variations. [19] [20] [21] The haplotype IL-10.R2/IL10.G14 was associated with highest IL-10 secretion overall, whereas the haplotype IL10.R3/IL10.G7 was associated with lowest IL-10 secretion. Thus, the ability to secrete IL-10 can vary in man according to the genetic composition of the IL-10 locus. 20 Recently we isolated the 5Ј-flanking region of IL-10 and characterized the promoter region. In the recent description of the IL-10 promoter we identified positive and negative regulatory elements within the 5Ј-flanking region of the IL-10 gene, including a silencing element between −681 and −313. 17 In addition the location of potential transcription factor binding motifs in the proxi-mal promoter of the IL-10 gene, thought to transduce signals from cytokines or other elements of the immune system, were described. 18 The expression of the human IL-10 gene is known to be influenced by other cytokines, particularly tumour necrosis factor (TNF). 19, 21 Several studies have demonstrated that, where gene transcription is influenced by TNF, the TNF influence is exerted through complexes of NFB, or cAMP-activated proteins. 19, [21] [22] [23] [24] In EBV-positive BL cell lines, IL-10 is constitutively expressed at high levels. 14, 15, 17, 25 In contrast, most EBV-negative BL cell lines do not express IL-10. [14] [15] [16] 25 The infection of normal B cells with EBV leads to an immortalization of these cells and the expression of IL-10 in vitro. 13 EBV, a ␥-herpesvirus, is detectable in a number of tumours including BL, Hodgkin's disease and nasopharyngeal carcinomas. The EBV latent membrane protein 1 (LMP 1) is a major component in the process of B cell immortalisation and transformation. [26] [27] [28] [29] [30] It has been shown that LMP1 induces phenotypic changes of B cells and activates cellular genes like CD40 or ICAM1/CD54, modulates the NFB and c-jun-N-terminal-kinase (JNK) pathway through functional domains within the Cterminal cytoplasmic part of LMP1. 28, [31] [32] [33] [34] [35] The expression of EBV LMP1 in BL cells, or HTLV-I tax in Jurkat cells induces IL-10 expression. 16, 36 Recently, it has been shown that three of the NFB sites were able to bind NFB in HTLV tax expressing human T cell lines, implicating a direct involvement of this transcription factor in virusassociated IL-10 expression. 36 It has been suggested that the activation of NFB by HTLV-I tax is the major cofactor for IL-10 activation. Thus these viral genes could mimic the function of cytokine receptors like that for TNF. 37, 38 Direct functional evidence for NF involvement in IL-10 expression is still missing.
The present study was designed to identify IL-10 promoter regions which might be important for the regulation of IL-10 by EBV in lymphoma cell lines.
Results

Constitutive expression of interleukin-10 is in part differentially regulated in EBV-positive and EBVnegative lymphoma cell lines
In a recent description of the IL-10 promoter, we identified positive and negative regulatory elements within the 5Ј-flanking region of the IL-10 gene. 17 By analysing IL-10 promoter deletions, these elements were further investigated in different B-lymphoma cell lines which express IL-10 constitutively. The regulation of the IL-10 promoter was analysed in the EBV-positive BL cell lines BL36 and BL74 and compared to the EBV-negative Blymphoma cell line BJAB. The analysis of the promoter regulation was focused to the 5Ј-flanking fragment from −681 to +1 from the transcriptional start site. A series of fragments encompassing the potential IL-10 initiation site and the transcriptional start site (+1) were placed upstream of the coding region of the luciferase gene. All vectors were characterized by a close overlap of the translational start site of IL-10 and the reporter gene. The corresponding IL-10/luciferase vector (10 g) and a CMV-␤-galactosidase-vector (0.5 g) were cotransfected into IL-10 producing lymphoma cell lines. Transfection was performed by electroporation and cellular extracts were assayed for luciferase and ␤-galactosidase activity 24 h post-transfection (in relative light units = rlu). Figure 1a shows the design of promoter deletion mutants of the IL-10 promoter used in the described experiments. 17, 18 Shown also are the putative silencing element, the NFBsite capable of binding NFB (−435) in HTLV-I tax expressing Jurkat cells and the cAMP-response element (CREB) (−381) involved in IL-10 regulation in monocytic cell lines 36 (C Platzer, personal communication). The transfection of reporter gene vectors containing different IL-10 promoter fragments into the EBV-positive BL cell line BL36 showed that the suggested silencing area was located around −680, because the activity of the luciferase was increased by shortening the promoter length from −681 to −556 (Figure 1b) . The IL-10 promoter fragment of 556-bp length showed the highest capacity to direct luciferase expression. The longest promoter fragment analysed here (681 bp) was only half as active as the 556-bp fragment, which further underlines the existence of a silencer region within the IL-10 promoter, now localized between −681 and −611. However additional factors were involved because the removal of an additional 100 bp from the IL-10 promoter fragment was associated with a further increase in promoter activity. This suggests that the main silencing activity is located between −681 and −611, but elements between −611 and −556 could be involved in addition in silencing IL-10 promoter activity.
Additional deletions of the promoter from −556 to −336 and −219 showed that there was only slightly decreased promoter activity detectable. This suggests that the NFB-site at −435 or the CREB-site at −381 were not involved in the constitutive expression of IL-10 in BL36 (Figure 1a and b) . The promoter fragment containing 75 bp of the 5Ј-flanking region of the IL-10 gene had about 50% of the activity of the promoter fragment containing 232 bp. This 75-bp fragment contains a TATAconsensus site. 17, 39 Because this site at −60 could be used as the initiation site for binding of the RNA-polymerase-II complex, a promoter fragment lacking the ͗TATAAAA͘ sequence, but still containing 52 bp of the 5Ј-flanking region of IL-10 was analysed. 39 This 52-bp promoter fragment showed a reduced promoter activity compared to the 75-bp fragment, however it was still active compared with a promoter empty control vector (basic). This indicates that the region between −75 and −52 is not necessary for basic promoter activity. Identical results were found for BL74 (data not shown).
The same IL-10 promoter constructs were transfected into the B cell line BJAB expressing IL-10 constitutively (Figure 1c ). The transfection of IL-10 promoter/luciferase constructs with deletions between the residues −681 and −219 showed nearly the same luciferase activity dependence from the IL-10-promoter fragment length as in BL36. The silencing region between −681 and −556 was not as active as in BL36. The removal of 14 bp from the −219 fragment led to a clear reduction in promoter activity. At −139 the promoter activity reached very low levels, and a further shortening of the IL-10 promoter fragments had only little to no effects on the activity of the IL-10 promoter.
The AT-rich region from −54 to −66 is important for EBV-associated regulation of the IL-10 promoter To map more carefully the regulatory DNA-sequence associated with the IL-10 gene, a series of linker scanning mutations starting up at position −312 and progressing to position −32 were prepared by PCR methods yielding a NotI/EcoRI site of 22 bp in place of the native IL-10 promoter sequence ( Figure 2 ). These reporter gene constructs were transfected into BL36 cells ( Figure 2 ). The mutations which affect the reporter gene activity could be used as an indication that the wild-type sequence in this area is involved in IL-10 promoter regulation. The 312-bp fragment was used, because it was able to direct luciferase gene expression as efficiently as the main IL-10 promoter and was free of silencing elements identified between −681 and −556. The activity of the promoter fragment without any mutation was defined as 100%. In BL36 cells, mutations in the area between −76 to −55 and −54 to −33 showed the most significant decrease in promoter activity, whereas mutations between −119/−318 did not alter promoter activity (Figure 2 ). The mutation of the region −54/−33 and −97/−76 also affected the promoter activity, but to a lesser extent compared with −76/−55. The area from −76 to −55 showed a more than three-fold reduced promoter activity compared to the wild-type promoter, suggesting that this area is important for transcriptional regulation of IL-10 in EBV-positive BL cells. This area is characterised by a high content of A and T nucleotides between −54 to −66 (AT-rich region) from the transcriptional start site of the IL-10 gene and contains a TATA-consensus sequence at −60.
Using the same IL-10 promoter mutations as for the analysis of BL36 cells, profound differences in the importance of promoter regions were identified in BJAB cells (Figure 2 ). The mutations in the area between −76 to −55 and −54 to −33 affecting the IL-10-promoter activity in BL36 cells showed no differences from the wild-type promoter element in BJAB. Two important areas were found in BJAB: the region between −207 and −142 was characterised by a reduced promoter activity, whereas the region between −119 and −76 was characterised by enhanced promoter activity. The potential CBF/NF-Y binding site at −207 was destroyed in the promoter fragment containing the linker scanning mutation at −207/−183. The reevaluation of the remaining part of this region from −182 to −139 revealed in addition the presence of potential binding sites for AP1-ATF3, NF-AT, the CD2 3Ј-enhancer and myb with a high score and a lower score for ISRE and the IL-4P3 site as defined by GCGsoftware usage (Figure 3) . 18 The reduced promoter activity in the linker scanning mutated fragments between −207 and−142 was in line with the results of the deletion promoter fragments (Figure 1c) . At −139 the promoter activity reached very low levels ( Figure  1c ). The enhanced promoter activity detected by linker scanning mutations in the region between −141 and −76 could explain the low activity of shorter wild-type IL-10 promoter fragments in BJAB compared to BL36, suggesting the presence of silencing elements in this area, active only in EBV-negative cell lines which express IL-10 constitutively (Figures 1c and 2) . . Since a TATA-consensus site was described in this area, the experiments were focused on the mutations where the T at −60 was converted to an A and the A at −57 to an T. Two IL-10 promoter fragments of different length were generated (Figure 4) . The transfection of these constructs showed that the mutation at −60 led to an inhibition of the IL-10 promoter-driven luciferase activity in BL36 and BL74 cells (Figure 4) . The mutation at −57 led to enhanced reporter gene activity independent from the deletion at −91. The same promoter 
The AT-rich region from −54 to −66 could act as an enhancer for EBV-associated transcriptional regulation of IL-10
To test whether the AT-rich region at −66 to −54 could play a role as an enhancing element in EBV-associated regulation of the IL-10 promoter, it was cloned as a triplicate element upstream from a ␤-globin basic promoter driving the expression of a luciferase gene. An oligomerised wild-type element (triplet) and the corresponding element containing the mutation T at −60 to an A were cloned into the GA50-7 vector. The activity of the basic promoter without any additional element was defined as 100%. The transfection into BL36 or BL74 of the construct containing the wild-type triplicate led to an about three-fold enhanced activity of the luciferase compared to the basic promoter, whereas the mutated triplicate led to a reduced luciferase activity ( Figure 5 ). The transfection of the same plasmids into BJAB cells showed no differences between the basic ␤-globin promoter activity and the introduced oligomerized AT-rich region. A slightly reduced luciferase activity was observed with the mutated region. These results reveal further that this region may play an important role in the EBV-associated regulation of the IL-10 promoter in lymphoma cells, where the T at −60 is essential.
Discussion
It has been shown that in contrast to normal hematopoietic cells in EBV-immortalized B cells and EBV-positive Burkitt lymphoma cells, IL-10 is constitutively expressed at high levels. The mechanism of the IL-10 expression was investigated in this presentation. The most critical element within the IL-10 promoter in EBV-positive constitutive IL-10 expressing BL cells is an AT-rich region between −66 and −54 as shown by linker scanning mutagenesis and point mutational analysis. This AT-rich region was in addition able to enhance the ␤-globin promoter activity. The absence of any influence of the AT-rich region on the luciferase activity from different plasmids in BJAB cells underlines the importance of this region in EBV-associated IL-10 regulation. At residue −60 a TATA-consensus site exists within this AT-rich region. The mutation TACAATATAA to TACAAAA-TAA was associated with a reduction of reporter gene activity in EBV-positive BL cell lines but not BJAB cells. The replacement TACAATATAA to TACAATATTA resulted in an activation of the reporter gene activity in BL36 and BL74 but not in BJAB, which further suggests that this area may function as a regulatory element in EBV-positive cells. Because to our knowledge neither mutation changes the potential of a TATA-consensus site for RNA-polymerase II binding, the effects detected in our experiments suggest that this AT-rich region may act as an EBV-associated enhancer. The distance of this potential TATA-sequence from the known start site of the transcript of IL-10 is 60 bp and thus at an unusual distance for RNA-polymerase II binding and transcription initiation. Normally the distance between the initiation of Figure 5 The AT-rich region could serve as an enhancer element in BL cells. Plasmids corresponding to GA50-7, GA50-7/3 × TA and GA50-7/3 × TAmut, were transiently transfected into BJAB (í), BL36 ( ), BL74 ( ) cells along with an internal reference plasmid expressing ␤-galactosidase under the control of a CMV-promoter. The activity of the IL-10 promoter is given as relative light units of luciferase activity in relation to ␤-galactosidase activity, both measured by enhanced chemoluminescence (rlu luc/␤gal) as described in Materials and Methods. GA50-7 is the vector containing a luciferase gene under the control of the basic ␤-globin promoter (␤-globin), GA50-7/3 × TA is the vector containing a luciferase gene under the control of the basic ␤-globin promoter and a triplicate of the native IL-10 AT-rich region (3 × (AGCTTACAATATAAAAGGGG)-␤-globin) and GA50-7/3 × TAmut is the vector containing a luciferase gene under the control of the basic ␤-globin promoter and a triplicate of the mutated IL-10 AT-rich region (3 × (AGCTTACAAAATAAAAGGGG)-␤-globin).
transcription (binding of the RNA-polymerase complex) and the transcriptional start site (5Ј end of the mRNA) is about 30 bp. [39] [40] [41] [42] [43] [44] This may also explain, why the deletion of the TATA-consensus sequence as shown in Figure 1b was associated only with a reduction but not complete loss of IL-10 promoter activity in BL cells. There exists a potential initiation site ͗ACAT͘ at −27 which is similar to a YY1 core binding sequence and could be the place for binding of the RNA-polymerase II complex to direct the expression of IL-10 in EBV-positive B cells. 45, 46 Another explanation for the reduced IL-10 promoter activity in the TACAAAATAA mutant could be the destruction of the imperfect NF-Y/CCAAT-site at this place.
The recently described silencer region between −681 and −313 was mapped here to −681/−556 with the high score to −681/−611. The YY1 site at −545 could be involved in part in this silencing. 17 The YY1-site is capable of binding YY1, a known transcriptional inhibitor, dependent on the surrounding sequences. However the cotransfection of IL-10 promoter fragments, together with a YY1 expression plasmid led to an overall inhibition of IL-10 promoter activity (own unpublished observation), suggesting that YY1 could be involved in IL-10 regulation in a more complex way. 47, 48 A potential initiation site at −27 which is similar to a YY1 core binding sequence could be a reason for this inhibition. 45, 46 In the area between −681 and −611 there are so far no known sequences for transcription factors identified which could act as a silencer.
EBV is able to activate a number of cellular genes in B cells including CD21, CD23, CD40 and CD54. 28, 34 It has been shown also that LMP1 alone is able to induce IL-10 in BL cells but the signaling cascades involved are not known. 16 The precise mechanisms are not yet fully understood. However it has been described that LMP1 triggers NFB and JNK/AP1 activities but clear links of the activation of both signal cascades to the known EBV-activated cellular genes are so far missing. 32, 35, 38, 49 Our experiments presented here show that the main promoter activity for IL-10 is located within 350 bp upstream from the transcriptional start site. In this area no consensus sequences for NFB or AP1 have been identified, thus revealing no direct involvement of these transcription factors in EBV-associated regulation of IL-10. This result supports the growing evidence that for EBV and particularely LMP1, signaling is rather complex and consists of a number of signal mediators like NFB or AP1 or complex interactions between both factors. 49 It has been reported that a mutant LMP1⌬187-351 (containing only the C-terminal activation region-2 (CTAR2) of the cytoplasmic C-terminus) is still able to activate CD54 to approximately 50% of wild-type LMP1 in B cell lines, whereas the ability to activate NFB differs and is cell line-dependent. 49 However the high number of transcription factor binding sites in addition to NFB or AP1 in the CD54 promoter or the lack of typical sites in the analysed IL-10-promoter region makes it possible that additional signal transduction pathways could be involved. 17, 23 In addition, the mutant LMP1⌬187-351 was unable to induce IL-10 and the expression of a dominant negative IB␣ did not lead to an inhibition of LMP1 associated IL-10 expression in BL2 cells. 50 The JNK pathway, activated through the CTAR2 of LMP1 is, like NFB, probably not directly involved in IL-10 promoter regulation. Although the signaling pathway is unknown, further analysis could be now focused on the identified AT-rich region, where the T at −60 may be important.
Mori and colleagues reported that the HTLVI tax protein induces IL-10 expression in Jurkat cells. 36 Three NFB sites within the 5Ј-flanking region of the IL-10 gene were able to bind NFB in HTLVI tax expressing human T-cells as shown by gel retardation experiments, suggest-ing a direct involvement of this transcription factor in virus-associated IL-10 expression. Our results indicate that these NFB-sites are not directly involved in the regulation of the main IL-10 promoter activity in B lymphoma cell lines. In addition it has been shown that in some cases the transactivation activity of NFB can be inhibited without inhibition of NFB binding to DNA, 51, 52 demonstrating the limitations of gel retardation experiments for functional NFB analysis. In another series of experiments using dominant negative IB-␣, we have shown that the EBV-associated expression of IL-10 is NFB-independent. 50 In addition we demonstrated that IL-10 could be regulated in transformed B cells through different promoter regions. Whereas in EBV-positive BL cells the AT-rich region between −66 and −54 was important, in the EBVnegative cell line BJAB two regions could play a role: −163/−142 and −207/−183 for positive regulation and −141/−76 for negative regulation of the IL-10 promoter activity. Using deletion mutants, very low promoter activity was detectable between residues −139 and +1 in BJAB cells. By linker scanning mutation analysis, it was shown that the disruption of the wild-type sequence between −141/−76 was associated with an increased promoter activity suggesting the action of silencing factors in this area in BJAB cells, absent in BL cells.
Our results now form a basis to identify proteins specifically binding to the AT-rich region for further detailed experiments in dissecting the mechanisms by which the IL-10 promoter is regulated.
Materials and methods
Construction of IL10/luciferase-fusion genes and experimental design DNA fragments containing various portions of the 5Ј-flanking region of the human IL10 gene were placed upstream of the luciferase gene in the vector pGL2-basic (enhancer-/promoterless) (Promega, Madison, WI, USA). The following fragments were generated as described previously: −75, −139, −313, −365 17 with an additional deletion of a SphI/HindIII fragment to bring closer the ATGs of IL-10 and the luciferase. The constructs −232 and −276 were kindly provided by P Dobrowolski using partial AluI digests. All used oligonucleotides were provided by Eurogentec (Belgium) ( Table 1 to A and deletions at A (−129), A (−91) were generated by PCR using Vent-exo − Polymerase (New England Biolabs, Beverly, MA, USA) with the following oligonucleotides: −176 and +29 rev. The amplimers were cloned into pGL2-basic by BglII/HindIII digestion. All amplified promoter fragments were sequenced before use.
The following oligonucleotides were used for insertion into the BamHI site of the vector GA50-7 (kindly provided by G Laux, Munich) containing a ␤-globin basic promoter and the firefly-luciferase gene: 3 × TA 5ЈGATCCAGCTTACAATATAAAAGGGGAGCTTACA ATATAAAAGGGGAGCTTACAATATAAAAGGG; 3 × TAmut 5ЈGATCCAGCTTACAAAATAAAAGGGGAGCTTAC AAAATAAAAGGGGAGCTTACAAAATAAAAGGG.
Cell lines and transfection
The Burkitt lymphoma cell lines BL36 and BL74 were provided by GM Lenoir (Lyon, France), BJAB was provided by E Kieff (Boston, MA, USA). The cells were grown in RPMI with 10% fetal calf serum (FCS) and glutamine/penicilline/streptomycine (all from SigmaAldrich, Deisenheim, Germany). The day before transfection cells were seeded with fresh media at a cell density of 2-4 × 10 5 cells/ml. Cells were washed with PBS twice and resuspended at a density of 1 × 10 7 cells/ml. Transfection was performed with 10 g CsCl purified DNA together with 0.5 g of a CMV-␤-galactosidase coding vector, which was used as an internal control to correct for variations in transfection efficiencies. All cells were transfected by electroporation using the easy-jet electroporator (Eurogentec, Seraing, Belgium). The following conditions were used for transfection: 1 × 10 7 BL36 cells were resuspended in 0.5 ml of RPMI/10% FCS/25 mm Hepes pH 7.5 at 4°C for 20 min, pulsed at 274 V/1850 F and directly transferred to 10 ml fresh media (RPMI 1640/10 mM Hepes pH 7.5 with 10% FCS). BJAB cells (1 × 10 7 ) were transfected as BL36 at 220 V/1800 F. BL74 were transfected as described previously. 17 Cells were grown for 24 h in RPMI with 10% FCS at 37°C, collected by centrifugation and lysed using 100 l of the reporter lysis buffer from the luciferase system (Promega, Heidelberg, Germany). Cell lysates were clarified by centrifugation and the protein concentration was determined using the Bradford method (Protein determination kit from Biorad, Hercules, CA, USA). Aliquots of lysate were then analysed for ␤-galactosidase activity, measuring the chemoluminescence of AMPGD substrate with Emerald luminescence enhancement (Galactolight, Tropix, USA) in a luminometer (Berthold, Germany). Equal amounts of cell lysate were used for determination of luciferase activity using beetle luciferin (Luciferase assay system, Promega).
The relative luminescence (rlu) was calculated as the ratio of luciferase to ␤-galactosidase activity. As positive control for transfection and luciferase activity, the pGL3-control-plasmid, containing the SV40-promoter and enhancer were used respectively (Promega). As background control the plasmids pGL2-basic, lacking the SV-40 promoter and enhancer, were used respectively. 
